The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
 
Brittany K. Ragon
No Relationships to Disclose
 
Anita D'Souza
Consulting or Advisory Role - Akcea Therapeutics; Bristol-Myers Squibb/Celgene; Janssen Oncology; Pfizer; Prothena
Research Funding - Abbvie; Caelum Biosciences (Inst); Janssen Oncology; Prothena (Inst); Regeneron; Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
Travel, Accommodations, Expenses - Imbrium Therapeutics
 
Noel Estrada-Merly
No Relationships to Disclose
 
Raphael Fraser
No Relationships to Disclose
 
Gemlyn George
No Relationships to Disclose
 
Lohith Gowda
Honoraria - Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene
 
Nina Shah
Consulting or Advisory Role - Amgen; CareDX; CSL Behring; Genentech/Abbvie; GlaxoSmithKline; Indapta Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Oncopeptides; Sanofi
Research Funding - Bluebird Bio; Celgene; Cellectis; Janssen; Nektar; poseida therapeutics; Precision Biosciences; Sutro biopharma; Teneobio
 
Muzaffar H. Qazilbash
Speakers' Bureau - Merck; Sanofi
Research Funding - Amgen; Angiocrine Bioscience; BioLineRx; Janssen
 
Shaji Kumar
Honoraria - BeiGene
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Cellectar; Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Molecular Partners (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); CARsgen Therapeutics (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
 
Mary M. Horowitz
Consulting or Advisory Role - Medac (Inst)
Research Funding - Actinium Pharmaceuticals (Inst); Amgen (Inst); Astellas Pharma (Inst); Biovitrum (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Chimerix (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Gamida Cell (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Kite/Gilead (Inst); Magenta Therapeutics (Inst); Mesoblast (Inst); Miltenyi Biotec (Inst); Novartis (Inst); Oncoimmune (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sanofi (Inst); Seagen (Inst); Shire (Inst); Xenikos (Inst)
 
Saad Zafar Usmani
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; Celgene; Genentech; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Merck; Oncopeptides; Seagen; Skyline Diagnostics; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology; Sanofi; Takeda
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Pharmacyclics; Sanofi; Seagen; Skyline Diagnostics
 
Mithun Vinod Shah
Research Funding - Archer